Tern appoints Rob Stevens as adviser on shareholder relations

TERN

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things technology businesses, has announced that the Board of Tern has appointed Robert (Rob) Stevens as an adviser to the Company on shareholder relations.

Mr Stevens, a private shareholder in the Company, brings experience of the UK small-cap investment community and will provide the Board with strategic advice and guidance, in conjunction with the Company’s other advisers, on investor communications and shareholder sentiment, to allow the Company to remain closely attuned to market views as it pursues its long-term value creation strategy.

The Board will continue to evaluate the appropriateness of appointing additional advisers in due course, as part of its ongoing commitment to enhancing shareholder engagement and value creation.

Conditional Grant of Options

Mr Stevens has conditionally been granted 1,000,000 options over ordinary shares of 0.02p each in the Company.

The grant and any exercise of the Conditional Options will be conditional on the Company obtaining the requisite authorities to satisfy the issue and allotment of any new Ordinary Shares resulting from the future potential exercise of the Conditional Options, which will involve the passing of a resolution at a future general meeting of shareholders.

Subject to the satisfaction of the Conditions, the Conditional Options will vest in equal monthly amounts over three years from the date of the satisfaction of the Conditions, and will be exercisable for a period of 10 years from the date of vesting at a price of 1.70p per Ordinary Share, being approximately double the mid-market closing price of the Ordinary Shares on 29 August 2025, the last practical date prior to this announcement.

Following the satisfaction of the Conditions, the total number of options outstanding over Ordinary Shares in Tern Plc will be 11,500,000.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority strengthens position in machine identity and Zero Trust Security

Device Authority’s inclusion in two 2026 Gartner Hype Cycle reports reinforces its positioning in machine identity, IoT authentication and Zero Trust security.

Talking Medicines highlights strategic value of patient journey intelligence

Patient journey intelligence can help healthcare organisations identify care barriers and design more responsive pathways around real patient experiences.

Evidence-based care pathways support more consistent healthcare delivery

Evidence-based care pathways can improve diagnosis, treatment consistency and the integration of new therapies into routine care.

Tern increases Talking Medicines funding and raises shareholder distribution commitment

Tern has invested in additional Talking Medicines convertible loan notes and increased its minimum shareholder distribution commitment to 70% on qualifying exits.

Evidence-based care pathways create clearer routes to adoption

Evidence-based care pathways can reduce delays, improve treatment consistency and support the adoption of new therapies.

Talking Medicines highlights the data opportunity emerging around GLP-1 care

Talking Medicines examines how the expanding GLP-1 market is increasing the importance of clear distinctions between approved therapies, compounded medicines and nutritional support.

Search